Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning
Release Date: July 24, 2015
Expiration Date: March 24, 2017
ESTIMATED TIME TO COMPLETE ACTIVITY:
The target audiences for these activities are surgeons, surgical oncologists, medical oncologists, physician assistants, nurse practitioners, and oncology nurses.
After completing this activity, the participant should be better able to:
- Evaluate biomarker expression, genetic screening results, and other clinical characteristics based on current evidence-based guidelines to screen all newly diagnosed patients for neoadjuvant therapy eligibility
- Counsel all breast cancer patients who are eligible for neoadjuvant therapy on the benefits and risks of pre-operative systemic therapy relative to other treatment approaches
- Collaborate with the multi-disciplinary cancer care team and the patient to develop an evidence-based treatment plan that considers patient quality of life and treatment goals
Hope S. Rugo, MD
University of California San Francisco
William Gradishar, MD
Northwestern’s Maggie Daley Center for Womens Cancer Care
Joanne Buzaglo, PhD
Cancer Support Community
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and On Q Health, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Hope S. Rugo, MD||Consulting Fees, Genomic Health; Contracted Research, Glaxo Smith Kline, Genentech, Roche, Novartis Pharmaceuticals, Merck & Company, Amgen, Eisai Co., Ltd., MacroGenics, Plexxikon, OBI, Astellas, PfizerUC Reagents|
|William Gradishar, MD||No real or apparent conflict of interest to report.|
|Joanne Buzaglo, PhD||No real or apparent conflict of interest to report.|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Carevive Systems, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Gilead Sciences; Karen Hammelef, DNP, RN, Speakers’ Bureau, Novartis Pharmaceuticals Corporation.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME credit for this activity. During the period July 24, 2015 through July 24, 2016 participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 10468. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
HARDWARE AND SOFTWARE REQUIREMENTS
CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.